Protein–protein interactions (PPIs) play a vital role in nature, and are involved in various disease areas including infectious disease, neurodegenerative disease, and notably cancer. The PPI between RAD51 and BRCA2 plays a key role in homologous recombination (HR), and aids the repair of double stranded DNA breaks. Impairment of the HR repair mechanism through BRCA2 mutations can lead to the sensitization of cancer cells to therapeutic DNA-damaging agents. It has been suggested that disruption of the RAD51-BRCA2 PPI could induce an artificial ‘BRCAness’ in tumors, opening the door for treatment with PARP inhibitors, of which four have received regulatory approval in the past ten years for patients with tumors showing BRCA2 mutations. In the pursuit of RAD51-BRCA2 disruptors, and after an initial 19F NMR ligand binding screening of approximately 900 fluorinated fragments against full-length RAD51, ARN2037 was identified as a RAD51 binder. The activity of this compound was evaluated through biochemical and biophysical techniques (Elisa: EC50 > 350 µM and MST: KD 1.23 ± 0.13 mM), confirming its activity as a RAD51 binder able to inhibit HR at 400µM in BxPC3 cells (fully functional BRCA2 human primary pancreatic adenocarcinoma) (IC50: 369µM). ARN2037 was further able to interfere with the disassembly of RAD51 fibrils by BRC4, in a time-dependent manner. However, given the weak binding of ARN2037, a medicinal chemistry program was undertaken that culminated in the discovery of the hit compound ARN24922 which outperformed ARN2037 across biochemical and biophysical assays (Elisa: EC50 100 ± 20 µM and MST: KD 10.48 ± 3.92 µM). A similar improvement was seen in HR inhibition (IC50: 9.06 ± 3 µM). We hope to further study ARN24922 as a potential tool in better understanding the mechanisms and effects that occur as a result of the PPI disruption between RAD51-BRCA2.

Identification and subsequent development of RAD51-BRCA2 disruptors through a fragment-based approach / Samuel Harry Myers , Viola Previtali, Laura Poppi, Francesco Rinaldi, Fabrizio Schipani, Jose Antonio Ortega, Francesca De Franco, Marina Veronesi, Roberto Pellicciari, Marinella Roberti, Stefania Girotto, Giuseppina Di Stefano, Andrea Cavalli. - ELETTRONICO. - (2022), pp. 1-1. (Intervento presentato al convegno ACS Spring 2022 tenutosi a San Diego Convention Center, Room 16A nel 20/03/2022).

Identification and subsequent development of RAD51-BRCA2 disruptors through a fragment-based approach

Laura Poppi;Francesco Rinaldi;Marinella Roberti;Giuseppina Di Stefano;Andrea Cavalli
2022

Abstract

Protein–protein interactions (PPIs) play a vital role in nature, and are involved in various disease areas including infectious disease, neurodegenerative disease, and notably cancer. The PPI between RAD51 and BRCA2 plays a key role in homologous recombination (HR), and aids the repair of double stranded DNA breaks. Impairment of the HR repair mechanism through BRCA2 mutations can lead to the sensitization of cancer cells to therapeutic DNA-damaging agents. It has been suggested that disruption of the RAD51-BRCA2 PPI could induce an artificial ‘BRCAness’ in tumors, opening the door for treatment with PARP inhibitors, of which four have received regulatory approval in the past ten years for patients with tumors showing BRCA2 mutations. In the pursuit of RAD51-BRCA2 disruptors, and after an initial 19F NMR ligand binding screening of approximately 900 fluorinated fragments against full-length RAD51, ARN2037 was identified as a RAD51 binder. The activity of this compound was evaluated through biochemical and biophysical techniques (Elisa: EC50 > 350 µM and MST: KD 1.23 ± 0.13 mM), confirming its activity as a RAD51 binder able to inhibit HR at 400µM in BxPC3 cells (fully functional BRCA2 human primary pancreatic adenocarcinoma) (IC50: 369µM). ARN2037 was further able to interfere with the disassembly of RAD51 fibrils by BRC4, in a time-dependent manner. However, given the weak binding of ARN2037, a medicinal chemistry program was undertaken that culminated in the discovery of the hit compound ARN24922 which outperformed ARN2037 across biochemical and biophysical assays (Elisa: EC50 100 ± 20 µM and MST: KD 10.48 ± 3.92 µM). A similar improvement was seen in HR inhibition (IC50: 9.06 ± 3 µM). We hope to further study ARN24922 as a potential tool in better understanding the mechanisms and effects that occur as a result of the PPI disruption between RAD51-BRCA2.
2022
ACS Spring 2022
1
1
Identification and subsequent development of RAD51-BRCA2 disruptors through a fragment-based approach / Samuel Harry Myers , Viola Previtali, Laura Poppi, Francesco Rinaldi, Fabrizio Schipani, Jose Antonio Ortega, Francesca De Franco, Marina Veronesi, Roberto Pellicciari, Marinella Roberti, Stefania Girotto, Giuseppina Di Stefano, Andrea Cavalli. - ELETTRONICO. - (2022), pp. 1-1. (Intervento presentato al convegno ACS Spring 2022 tenutosi a San Diego Convention Center, Room 16A nel 20/03/2022).
Samuel Harry Myers , Viola Previtali, Laura Poppi, Francesco Rinaldi, Fabrizio Schipani, Jose Antonio Ortega, Francesca De Franco, Marina Veronesi, Ro...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/929676
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact